---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-116475"
form_type: "8-K"
ticker: "ARMP"
cik: "0000921114"
company_name: "Armata Pharmaceuticals, Inc."
filed_at: "2022-11-09T23:59:59+00:00"
generated_at: "2026-06-22T02:33:48.951283+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Armata Pharma Q3 2022 loss widens to $8.6M; cash at $25.4M; SWARM-P.a. study near completion

## Summary
- Loss from operations $(8.6)M in Q3 2022 vs $(6.1)M in Q3 2021, driven by higher R&D spending.
- Cash and equivalents $25.4M as of Sept 30, 2022, up from $10.3M at Dec 31, 2021; expects $16.3M in MTEC grant funding.
- R&D expenses $8.4M, up from $5.6M; G&A expenses $1.6M, down from $1.8M.
- SWARM-P.a. Phase 2 MAD cohort enrollment finishing in Q4; top-line data expected early 2023.
- AP-SA02 bacteremia study enrolling Phase 1b; regulatory approvals in Australia to accelerate enrollment.

## SEC filing metadata
- accession: 0001104659-22-116475
- form_type: 8-K
- ticker: ARMP
- cik: 0000921114
- company_name: Armata Pharmaceuticals, Inc.
- filed_at: 2022-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/921114/000110465922116475/0001104659-22-116475-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/921114/000110465922116475/tm2226320d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-116475
- JSON: https://secwatch.observer/filing/0001104659-22-116475.json
- Plain text: https://secwatch.observer/filing/0001104659-22-116475.txt

## Key facts
- Earnings Releases
  Armata Pharmaceuticals, Inc. reported the three months ended September 30, 2022 results: revenue $1.3 million, net income $(8.6) million.
  - Period: the three months ended September 30, 2022
  - Revenue: $1.3 million
  - Net income: $(8.6) million
  - Result: reported results
  source text: Third Quarter 2022 Financial Results Grant Revenue. The Company recognized grant revenue of approximately $1.3 million for the three months ended September 30, 2022, which represents Medical Technology Enterprise Consortium (“MTEC”)’s share of the costs incurred for the Company’s AP-SA02 program for the treatment of Staphylococcus aureus bacteremia. The Company expects to receive $16.3 million in grant funding from MTEC administered by the U.S. Department of Defense and the Defense Health Agency and Joint Warfighter Medical Research Program. The Company recognized approximately $1.3 million of revenue in the comparable period in 2021. Research and Development. Research and development expenses for the three months ended September 30, 2022, were approximately $8.4 million as compared to approximately $5.6 million for the comparable period in 2021. The company continues to invest in clinical trial and personnel related expenses associated with its primary development programs. General an
  evidence_url: https://www.sec.gov/Archives/edgar/data/921114/000110465922116475/0001104659-22-116475-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.